Evidence map›Paper›PMID 23417677›Full record

ArticleThe Journal of biological chemistry2013

Identification of tribbles-1 as a novel binding partner of Foxp3 in regulatory T cells.

Emilie Dugast, Endre Kiss-Toth, Louise Docherty, Richard Danger, Mélanie Chesneau, Virginie Pichard, Jean-Paul Judor, Ségolène Pettré, Sophie Conchon, Jean-Paul Soulillou and 2 more

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Pseudokinase STK40 promotes TScience advances · 2024
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Emilie DugastUMR1064, Institut National de la Santé et de la Recherche Médicale, Nantes 44000, France; Faculté de Médecine Université de Nantes, Nantes 44000, France; TcLand Expression, 21 rue de la Noue Bras de Fer, 44200 Nantes, France; Institut de Recherche en Transplantation, Institut de Transplantation Urologie-Néphrologie, Nantes 44000, France.
Endre Kiss-TothDepartment of Cardiovascular Science, University of Sheffield, Sheffield S10 2TN, United Kingdom.
Louise DochertyDepartment of Cardiovascular Science, University of Sheffield, Sheffield S10 2TN, United Kingdom.
Richard DangerUMR1064, Institut National de la Santé et de la Recherche Médicale, Nantes 44000, France; Faculté de Médecine Université de Nantes, Nantes 44000, France; Institut de Recherche en Transplantation, Institut de Transplantation Urologie-Néphrologie, Nantes 44000, France.
Mélanie ChesneauUMR1064, Institut National de la Santé et de la Recherche Médicale, Nantes 44000, France; Faculté de Médecine Université de Nantes, Nantes 44000, France; Institut de Recherche en Transplantation, Institut de Transplantation Urologie-Néphrologie, Nantes 44000, France.
Virginie PichardUMR1064, Institut National de la Santé et de la Recherche Médicale, Nantes 44000, France; Faculté de Médecine Université de Nantes, Nantes 44000, France; Institut de Recherche en Transplantation, Institut de Transplantation Urologie-Néphrologie, Nantes 44000, France.
Jean-Paul JudorUMR1064, Institut National de la Santé et de la Recherche Médicale, Nantes 44000, France; Faculté de Médecine Université de Nantes, Nantes 44000, France; Institut de Recherche en Transplantation, Institut de Transplantation Urologie-Néphrologie, Nantes 44000, France.
Ségolène PettréUMR1064, Institut National de la Santé et de la Recherche Médicale, Nantes 44000, France; Faculté de Médecine Université de Nantes, Nantes 44000, France; Institut de Recherche en Transplantation, Institut de Transplantation Urologie-Néphrologie, Nantes 44000, France.
Sophie ConchonUMR1064, Institut National de la Santé et de la Recherche Médicale, Nantes 44000, France; Faculté de Médecine Université de Nantes, Nantes 44000, France; Institut de Recherche en Transplantation, Institut de Transplantation Urologie-Néphrologie, Nantes 44000, France.
Jean-Paul SoulillouUMR1064, Institut National de la Santé et de la Recherche Médicale, Nantes 44000, France; Institut de Recherche en Transplantation, Institut de Transplantation Urologie-Néphrologie, Nantes 44000, France; Centre Hospitalier Universitaire de Nantes, Nantes 44000, France.
Sophie BrouardUMR1064, Institut National de la Santé et de la Recherche Médicale, Nantes 44000, France; Institut de Recherche en Transplantation, Institut de Transplantation Urologie-Néphrologie, Nantes 44000, France; Centre Hospitalier Universitaire de Nantes, Nantes 44000, France. Electronic address: sophie.brouard@univ-nantes.fr.
Joanna Ashton-ChessTcLand Expression, 21 rue de la Noue Bras de Fer, 44200 Nantes, France. Electronic address: jashtonchess@tcland-expression.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a previous study, we identified TRIB1, a serine-threonine kinase-like molecule, as a biomarker of chronic antibody-mediated rejection of human kidneys when measured in peripheral blood mononuclear cells. Here, we focused our analysis on a specific subset of peripheral blood mononuclear cells that play a dominant role in regulating immune responses in health and disease, so-called CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs). We isolated both human and murine Treg and non-Treg counterparts and analyzed TRIB1 and Foxp3 mRNA expression by quantitative PCR on the freshly isolated cells or following 24 h of activation. Physical interaction between the human TRIB1 and Foxp3 proteins was analyzed in live cell lines by protein complementation assay using both flow cytometry and microscopy and confirmed in primary freshly isolated human CD4(+)CD25(hi)CD127(-) Tregs by co-immunoprecipitation. Both TRIB1 and Foxp3 were expressed at significantly higher levels in Tregs than in their CD4(+)CD25(-) counterparts (p < 0.001). Moreover, TRIB1 and Foxp3 mRNA levels correlated tightly in Tregs (Spearman r = 1.0; p < 0.001, n = 7), but not in CD4(+)CD25(-) T cells. The protein complementation assay revealed a direct physical interaction between TRIB1 and Foxp3 in live cells. This interaction was impaired upon deletion of the TRIB1 N-terminal but not the C-terminal domain, suggesting an interaction in the nucleus. This direct interaction within the nucleus was confirmed in primary human Tregs by co-immunoprecipitation. These data show a direct relationship between TRIB1 and Foxp3 in terms of their expression and physical interaction and highlight Tribbles-1 as a novel binding partner of Foxp3 in Tregs.

Indexed as

AnimalsBiomarkersCD4-Positive T-LymphocytesCell AdhesionCell CycleCell ProliferationCell SurvivalDNA, ComplementaryForkhead Transcription FactorsGenetic Complementation TestHEK293 CellsHumansInterleukin-2 Receptor alpha SubunitInterleukin-7 Receptor alpha SubunitIntracellular Signaling Peptides and ProteinsLeukocytes, MononuclearBiomarkersDNA, ComplementaryForkhead Transcription FactorsFOXP3 protein, humanFoxp3 protein, mouseInterleukin-2 Receptor alpha SubunitInterleukin-7 Receptor alpha SubunitIntracellular Signaling Peptides and ProteinsProtein Serine-Threonine KinasesRNA, MessengerTRIB1 protein, humanTrib1 protein, mouse

Identifiers

PMID23417677
PMCPMC3617243

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.